Bavituximab is being tested in human beings in the United States on lung, liver, pancreatic, prostate and breast cancers as well as hepc by company sponsored and independent research docs.
I've bet my money that it will improve on the SOC in at least one of these, which IMO will trigger a lucrative partnership agreement or outright buyout. If I'm wrong, I'll lose a lot money. If I'm right I'll make much more money than I've wagered.
I enjoy the ride, despite the well-meaning(?) and realistic(?) pessimistic opinions I encounter regarding PPHM.
Happy in my investments,
Paul
Market Data 
Markets 
AI
